NCT03717896View on ClinicalTrials.gov

Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

September 30, 2024

Study Completion Date

October 1, 2024

Conditions
Diabetic Ketoacidosis
Interventions
DRUG

200mg IV thiamine in 50mL 0.9% saline

Thiamine 200mg IV every 12 hours for 2 days

DRUG

Placebo

50mL 0.9% saline

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03717896 - Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis | Biotech Hunter | Biotech Hunter